Add BrightSurf on Google Email

Phase 3 SWOG Cancer Research Network trial, led by a City of Hope researcher, demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy

The Phase 3 S1826 trial demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma treated with nivolumab and chemotherapy. The therapy was well-tolerated, with few serious immune-related side effects.

SourceSWOG Cancer Research Network·TypeRandomized controlled/clinical trial·DateJun 4, 2023

ASCO: Targeted therapy for early breast cancer, progress treating recurrent glioma, PSMA PET scan advances and more

Researchers from the UCLA Jonsson Comprehensive Cancer Center are presenting findings on combination therapies for breast cancer and a potential new treatment for patients with recurrent glioma. A phase 3 study evaluating vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation is also be...

How can we fight blood cancer more effectively?

Researchers at ETH Zurich have developed a new method called pharmacoscopy to test treatment options for multiple myeloma patients. This high-throughput screening platform analyzes the reactions of cancer cells to various treatments, offering personalized therapeutic strategies.

SourceETH Zurich·JournalNature Cancer·TypeObservational study·DateApr 27, 2023

Differentiation landscape of acute myeloid leukemia charted with new tool

A new method, CloneTracer, distinguishes between cancerous and healthy stem cells in acute myeloid leukemia (AML). The study reveals two distinct stem cell compartments and shows that progenitor cells respond better to therapy. This finding paves the way for developing new techniques to predict patient response to chemotherapy.

SourceCenter for Genomic Regulation·JournalCell Stem Cell·TypeExperimental study·DateApr 24, 2023

Scientists create powerful, most-accurate tools to research deadliest blood cancer, study says

Researchers at The Mount Sinai Hospital have created versatile disease models of acute myeloid leukemia (AML), allowing for accurate study of the cancer's progression and response to drugs. These models, derived from induced pluripotent stem cells, can mimic different stages of AML and are nearly identical to those found in patients.

Combination therapy overcomes BET inhibitor resistance

Researchers at St. Jude Children's Research Hospital developed a novel combination therapy approach that uses both BET and GSK3 inhibitors against KMT2A mutated leukemia, overcoming drug resistance without increasing toxicity. The approach was confirmed in cell lines and xenograft mouse models, and holds promise for further development.

SourceSt. Jude Children's Research Hospital·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateApr 10, 2023

Impact of cortactin in cancer progression

Researchers discuss cortactin's impact on cancer progression by modulating the Wnt5a/ROR1 signaling pathway. Cortactin expression is found in various cancers, including breast and chronic lymphocytic leukemia, suggesting its potential role in promoting metastasis.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateApr 4, 2023

COVID vaccine induces robust T cell responses in blood cancer patients

Researchers found that COVID-19 vaccination generates robust T cell responses in haematology patients, on par with healthy individuals. The study provides key insights for future immunisation strategies and shows that mRNA vaccines can elicit strong T cell immunity in patients with co-morbidities.

SourceThe Peter Doherty Institute for Infection and Immunity·JournalCell Reports Medicine·TypeObservational study·DateMar 28, 2023

Why does a leukemic mutation not always lead to leukemia? A new clue from a mouse study at USC

Scientists from USC Stem Cell laboratory discovered a mechanism linking leukemic mutations to varying disease potentials, identifying RNA splicing regulator Rbm25 as a critical factor. The study found that over-contributing clones of blood stem cells produce excessive myeloid cells, leading to potential leukemia development.

SourceKeck School of Medicine of USC·JournalBlood·TypeExperimental study·DateMar 23, 2023

New targets for CAR-T cell therapy against acute myeloid leukemia through AI-assisted analysis

Researchers have identified two potential molecular targets, CSF1R and CD86, that can be used to develop CAR-T cells effective against acute myeloid leukemia. The study's findings demonstrate the potential of AI-assisted analysis in discovering new treatment options.

Cause of leukemia in trisomy 21

Children with Down syndrome are highly vulnerable to developing aggressive leukaemia due to a defect in the RUNX1 gene, which regulates blood cell formation. Researchers have identified a specific variant of the gene that promotes leukaemia development and discovered potential therapeutic approaches to correct this malfunction.

SourceGoethe University Frankfurt·JournalBlood·TypeExperimental study·DateMar 10, 2023

Vitamin B5 could help improve red blood cell production in people with Myelodysplastic syndromes

Researchers have discovered that the enzyme COASY plays a critical role in regulating red blood cell production in the bone marrow. Vitamin B5 supplementation and another metabolite increased the maturation of red blood cells in patients with Myelodysplastic syndromes, offering new hope for alternative treatments.

SourceThe Francis Crick Institute·JournalScience Translational Medicine·TypeExperimental study·DateMar 1, 2023

Pusan National University researchers uncover novel gene that regulates leukemia development and progression

Pusan National University researchers have identified a novel gene, SURF4, that regulates cell death and differentiation in acute myeloid leukemia (AML). The study found that suppressing SURF4 expression increases cell differentiation, cell death, and accumulation of ROS, leading to arrested tumor growth in mice.

SourcePusan National University·JournalCancer Communications·TypeExperimental study·DateJan 31, 2023

Chemotherapy in the afternoon dramatically improves treatment outcomes in female lymphoma patients

Researchers found that female patients with diffuse large B-cell lymphoma treated in the afternoon had reduced mortality rates and cancer recurrence compared to those treated in the morning. The study suggests that timing chemotherapy delivery according to an individual's circadian clock may improve treatment outcomes.

SourceInstitute for Basic Science·JournalJCI Insight·TypeRandomized controlled/clinical trial·DateJan 24, 2023

Optimal genome mapping offers high-resolution method to better see, then target cancer-causing gene variants

A new study standardizes the use of optical genome mapping (OGM) for patients with blood cancers, demonstrating its potential as a frontline test for diagnosing hematologic malignancies. OGM outperforms existing tests in detecting cancer-causing gene variants and identifying additional information that can improve patient outcomes.

SourceMedical College of Georgia at Augusta University·JournalJournal of Molecular Diagnostics·DateJan 17, 2023

Unlocking cancer’s ancestry

A new software developed by researchers at Cold Spring Harbor Laboratory can accurately infers continental ancestry from tumor DNA and RNA. This technology has the potential to lead to more targeted and personalized cancer treatments by identifying genetic connections between cancer and race or ethnicity.

SourceCold Spring Harbor Laboratory·JournalCancer Research·DateDec 27, 2022

A unique clinical trial leads to a dramatic decrease in early deaths from the rare and aggressive—yet highly curable—acute promyelocytic leukemia (APL)

A unique clinical trial has achieved a remarkable 97% induction survival rate in patients with acute promyelocytic leukemia (APL) by providing a simplified treatment regimen and 24/7 support from APL experts. This collaborative care model, known as EA9131, significantly reduced early deaths and improved overall survival rates.

Extending chemo slashes risk of aggressive childhood leukemia coming back

A new treatment protocol has been shown to significantly reduce the risk of aggressive childhood leukemia returning after chemotherapy. The ALL-11 protocol, which includes an extra year of maintenance chemotherapy for children with specific genetic mutations, has improved five-year survival rates and quality of life for these patients....

SourcePrincess Máxima Center for Pediatric Oncology·TypeRandomized controlled/clinical trial·DateDec 10, 2022

Experimental cancer therapy shows success in more than 70% of patients in global clinical trials

Researchers from The Mount Sinai Hospital found that talquetamab, a bispecific antibody, was successful in killing multiple myeloma cells in over 70% of patients. This therapy directs the immune system to target cancer cells and has shown promise even for those who have resisted all other treatments.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNew England Journal of Medicine·DateDec 10, 2022

Mount Sinai study uncovers inflammatory markers that may predict a response in certain patients to COVID-19 immunotherapies

A Mount Sinai study found that certain inflammatory markers can predict which patients are more likely to respond to COVID-19 immunotherapies. The researchers identified a subtype of COVID-19 patients with hyperinflammation who could benefit from pacritinib, an anti-cancer drug.